Triple-Drug attack aims to beat rare lymphoma
NCT ID NCT07457177
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests a combination of three drugs—golidocitinib, pegaspargase, and an immunotherapy—as a first treatment for advanced NK T-cell lymphoma, a rare and aggressive cancer. The study will enroll 40 people who have not had prior therapy. The goal is to see if this combo can shrink tumors and improve survival, while monitoring for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Golidocitinib (a JAK inhibitor), pegaspargase (a chemotherapy drug), and an anti-PD-1 monoclonal antibody (an immunotherapy)
What this could lead to
If this works, it could offer a more effective first-line treatment for advanced NK T-cell lymphoma, potentially improving survival rates.
What could go wrong
This is an early phase 2 trial with only 40 participants, so results may not apply to everyone. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NK/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••